Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > POC in humans has been acheived is that it

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on May 02, 2024 5:45pm

125 Views

Post# 36020492

RE:RE:RE:RE:RE:RE:RE:POC in humans has been acheived is that it

That is correct but they could have made an announcement of any really good data before committing to the conference. And given how badly things have been going for THTX, an early announcement might have been quite tempting if they really had fantastic info to report.

We have to hope there is something that is intriguing in whatever they release at the conference that increases our hope they may get the results we are looking for in part 3. Something that is better than what thye have already disclosed about part 1 and part 2. That, I believe, is the most we can hope for from this part 1 and part 2 long term data. IF they did have some blockbuster news coming from this data and did not report it earlier then we would all once again be left scratching our heads about how they communicate.